Expression of Thomsen-Friedenreich Antigen in Colorectal Cancer and Association with Microsatellite Instability.
O-glycan
Thomsen–Friedenreich antigen
colorectal cancer
glycosylation
microsatellite instability
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 Jan 2021
29 Jan 2021
Historique:
received:
29
12
2020
revised:
21
01
2021
accepted:
26
01
2021
entrez:
12
2
2021
pubmed:
13
2
2021
medline:
17
4
2021
Statut:
epublish
Résumé
Microsatellite instability (MSI) is a molecular phenotype due to a deficient DNA mismatch repair (dMMR). In colorectal cancer (CRC), dMMR/MSI is associated with several clinical and histopathological features, influences prognosis, and is a predictive factor of response to therapy. In daily practice, dMMR/MSI profiles are identified by immunohistochemistry and/or multiplex PCR. The Thomsen-Friedenreich (TF) antigen was previously found to be a potential single marker to identify MSI-high gastric cancers. Therefore, in this study, we aimed to disclose a possible association between TF expression and MSI status in CRC. Furthermore, we evaluated the relationship between TF expression and other clinicopathological features, including patient survival. We evaluated the expression of the TF antigen in a cohort of 25 MSI-high and 71 microsatellite stable (MSS) CRCs. No association was observed between the expression of the TF antigen and MSI-high status in CRC. The survival analysis revealed that patients with MSI-high CRC showed improved survival when the TF antigen was expressed. This finding holds promise as it indicates the potential use of the TF antigen as a biomarker of better prognosis in MSI-high CRCs that should be validated in an independent and larger CRC cohort.
Identifiants
pubmed: 33572915
pii: ijms22031340
doi: 10.3390/ijms22031340
pmc: PMC7866256
pii:
doi:
Substances chimiques
Antigens, Tumor-Associated, Carbohydrate
0
Thomsen-Friedenreich antigen
3554-90-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fundação para a Ciência e a Tecnologia
ID : UID/BIM/4293
Organisme : Fundação para a Ciência e a Tecnologia
ID : PTDC/BBB-EBI/0567/2014
Organisme : Programa Operacional Temático Factores de Competitividade
ID : POCI-01-0145-FEDER-007274
Organisme : Programa Operacional Temático Factores de Competitividade
ID : POCI-01-0145-FEDER-016585
Références
Cancer. 1995 Nov 15;76(10):1700-8
pubmed: 8625037
J Natl Cancer Inst. 2004 Feb 18;96(4):261-8
pubmed: 14970275
Cancer Cell. 2019 Jul 8;36(1):6-16
pubmed: 31287993
Nat Rev Immunol. 2018 Mar;18(3):204-211
pubmed: 29398707
Adv Cancer Res. 2015;126:53-135
pubmed: 25727146
Histopathology. 2020 Aug 13;:
pubmed: 32791559
Nature. 1993 Jun 10;363(6429):558-61
pubmed: 8505985
J Natl Cancer Inst. 2011 Jun 8;103(11):841-4
pubmed: 21597023
Mol Aspects Med. 2019 Oct;69:2-9
pubmed: 31233770
Biochim Biophys Acta. 2016 Aug;1860(8):1795-808
pubmed: 26721331
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
PLoS One. 2013;8(3):e59792
pubmed: 23536887
J Clin Pathol. 1987 Sep;40(9):1016-23
pubmed: 3312296
J Clin Oncol. 2005 Jan 20;23(3):609-18
pubmed: 15659508
J Biol Chem. 2007 Jan 5;282(1):773-81
pubmed: 17090543
Biochemistry (Mosc). 2015 Jul;80(7):801-7
pubmed: 26541995
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
J Clin Oncol. 2010 Jul 10;28(20):3219-26
pubmed: 20498393
Arch Pathol Lab Med. 2019 Oct;143(10):1225-1233
pubmed: 30917047
Science. 1993 May 7;260(5109):816-9
pubmed: 8484122
Oncotarget. 2018 Apr 10;9(27):18698-18711
pubmed: 29721154
J Biol Chem. 2003 Feb 7;278(6):4127-34
pubmed: 12438311
Oncotarget. 2014 Apr 30;5(8):2096-106
pubmed: 24758762
Ann Oncol. 2012 Oct;23(10):2479-2516
pubmed: 23012255
EMBO Rep. 2006 Jun;7(6):599-604
pubmed: 16741504
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Histochem Cell Biol. 1996 Aug;106(2):197-207
pubmed: 8877380
Cancers (Basel). 2019 Oct 15;11(10):
pubmed: 31618962
Carbohydr Res. 2017 Apr 18;443-444:58-67
pubmed: 28355582
Br J Surg. 2004 Apr;91(4):469-75
pubmed: 15048750
Adv Cancer Res. 2015;126:203-56
pubmed: 25727149
Cancer Lett. 2017 Feb 28;387:32-45
pubmed: 26828132
Hum Pathol. 2010 Oct;41(10):1387-96
pubmed: 20573374
Ann Oncol. 2020 Oct;31(10):1291-1305
pubmed: 32702383
Eur J Cancer. 2018 May;95:112-116
pubmed: 29519639
Expert Rev Mol Diagn. 2016;16(5):591-604
pubmed: 26895074
J Clin Pathol. 2010 Apr;63(4):322-9
pubmed: 20354203
Mol Cell Proteomics. 2015 Jun;14(6):1616-29
pubmed: 25813380
Nature. 2014 Jul 17;511(7509):319-25
pubmed: 25030168
Lancet Oncol. 2017 Sep;18(9):1141-1142
pubmed: 28734760
Int J Cancer. 2004 Sep 1;111(3):388-97
pubmed: 15221966
J Gastrointest Cancer. 2017 Dec;48(4):305-313
pubmed: 28699072
Front Oncol. 2019 May 14;9:396
pubmed: 31139574
Eur J Cancer. 2010 Oct;46(15):2788-98
pubmed: 20627535
Exp Mol Pathol. 2020 Oct;116:104519
pubmed: 32822722
Gastroenterology. 2010 Jun;138(6):2073-2087.e3
pubmed: 20420947
Mol Cancer. 2004 Aug 06;3:21
pubmed: 15298707
J Proteome Res. 2009 Feb;8(2):425-6
pubmed: 19133724
N Engl J Med. 2003 Jul 17;349(3):247-57
pubmed: 12867608
Nat Commun. 2016 Aug 30;7:12632
pubmed: 27572267
J Clin Med. 2018 Sep 05;7(9):
pubmed: 30189652
HLA. 2016 Dec;88(6):275-286
pubmed: 27679419
Nat Rev Cancer. 2015 Sep;15(9):540-55
pubmed: 26289314
Gastroenterology. 2020 Jan;158(2):291-302
pubmed: 31622622
Cancer Immunol Immunother. 2007 Aug;56(8):1225-36
pubmed: 17195076
Cancer Res. 2004 Oct 1;64(19):7050-7
pubmed: 15466199
Am J Gastroenterol. 2013 Nov;108(11):1785-93
pubmed: 24042191
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Glycobiology. 1993 Apr;3(2):97-130
pubmed: 8490246
Curr Treat Options Oncol. 2015 Jul;16(7):30
pubmed: 26031544
Front Biosci (Elite Ed). 2011 Jun 01;3:1443-55
pubmed: 21622148
J Mol Diagn. 2008 Jul;10(4):293-300
pubmed: 18556767
Colorectal Dis. 2012 Jan;14(1):3-17
pubmed: 21040359